CL2007003065A1 - Compounds derived from benzodioxane, 5ht2c agonist, pharmaceutical composition that you understand; and its use in the treatment of a psychotic disorder, anxiety, depression, bipolar disorder, premenstrual syndrome, among others - Google Patents
Compounds derived from benzodioxane, 5ht2c agonist, pharmaceutical composition that you understand; and its use in the treatment of a psychotic disorder, anxiety, depression, bipolar disorder, premenstrual syndrome, among othersInfo
- Publication number
- CL2007003065A1 CL2007003065A1 CL2007003065A CL2007003065A CL2007003065A1 CL 2007003065 A1 CL2007003065 A1 CL 2007003065A1 CL 2007003065 A CL2007003065 A CL 2007003065A CL 2007003065 A CL2007003065 A CL 2007003065A CL 2007003065 A1 CL2007003065 A1 CL 2007003065A1
- Authority
- CL
- Chile
- Prior art keywords
- benzodioxane
- anxiety
- depression
- pharmaceutical composition
- understand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Compuestos derivados de benzodioxano; composición farmacéutica que comprende a dichos compuestos; y su uso para tratar una enfermedad seleccionada entre trastornos psicóticos, tales como ansiedad, depresión, trastorno bipolar, síndrome premenstrual, entre otros.Compounds derived from benzodioxane; pharmaceutical composition comprising said compounds; and its use to treat a disease selected from psychotic disorders, such as anxiety, depression, bipolar disorder, premenstrual syndrome, among others.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85405506P | 2006-10-24 | 2006-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007003065A1 true CL2007003065A1 (en) | 2008-01-25 |
Family
ID=38941237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2007003065A CL2007003065A1 (en) | 2006-10-24 | 2007-10-24 | Compounds derived from benzodioxane, 5ht2c agonist, pharmaceutical composition that you understand; and its use in the treatment of a psychotic disorder, anxiety, depression, bipolar disorder, premenstrual syndrome, among others |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR063373A1 (en) |
CL (1) | CL2007003065A1 (en) |
TW (1) | TW200823187A (en) |
WO (1) | WO2008052086A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009063992A1 (en) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Condensed pyridine derivative and use thereof |
JPWO2011071136A1 (en) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | Fibromyalgia treatment |
US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
US9662339B2 (en) | 2012-03-06 | 2017-05-30 | Boehringer Ingelheim International Gmbh | Benzodioxane inhibitors of leukotriene production for combination therapy |
JP6256467B2 (en) | 2012-07-17 | 2018-01-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyrazole derivatives that inhibit leukotriene formation |
EP3022193B1 (en) | 2013-07-15 | 2017-04-26 | Boehringer Ingelheim International GmbH | Inhibitors of leukotriene production |
EP3022194B1 (en) | 2013-07-15 | 2017-05-17 | Boehringer Ingelheim International GmbH | Inhibitors of leukotriene production |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
GB201801128D0 (en) * | 2018-01-24 | 2018-03-07 | Univ Oxford Innovation Ltd | Compounds |
AU2022303386A1 (en) * | 2021-07-02 | 2023-12-14 | Aldeyra Therapeutics, Inc. | Heterocyclic aldehyde trapping compounds and uses thereof |
CA3221177A1 (en) | 2021-11-01 | 2023-05-04 | Meghan Kerrisk Campbell | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2791675B1 (en) * | 1999-03-30 | 2001-05-04 | Synthelabo | DERIVATIVES OF N- [2- (4-AMINOPHENYL) ETHYL] -2,3-DIHYDRO-1,4- BENZODIOXINNE-2-METHANAMINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
CA2380531A1 (en) * | 1999-07-29 | 2001-02-08 | Mark Louis Heiman | Benzofurylpiperazine serotonin agonists |
JP4047723B2 (en) * | 2000-10-16 | 2008-02-13 | エフ.ホフマン−ラ ロシュ アーゲー | Indoline derivatives and their use as 5-HT2 receptor ligands |
SE0201544D0 (en) * | 2002-05-17 | 2002-05-17 | Biovitrum Ab | Novel compounds and thier use |
JP2008538575A (en) * | 2005-04-22 | 2008-10-30 | ワイス | Benzodioxane and benzodioxolane derivatives and their use |
-
2007
- 2007-10-24 TW TW096139848A patent/TW200823187A/en unknown
- 2007-10-24 AR ARP070104705A patent/AR063373A1/en unknown
- 2007-10-24 WO PCT/US2007/082450 patent/WO2008052086A1/en active Application Filing
- 2007-10-24 CL CL2007003065A patent/CL2007003065A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200823187A (en) | 2008-06-01 |
AR063373A1 (en) | 2009-01-21 |
WO2008052086A1 (en) | 2008-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007003065A1 (en) | Compounds derived from benzodioxane, 5ht2c agonist, pharmaceutical composition that you understand; and its use in the treatment of a psychotic disorder, anxiety, depression, bipolar disorder, premenstrual syndrome, among others | |
CL2007002971A1 (en) | COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS. | |
CL2012001673A1 (en) | Substituted benzamide derivative compounds, as modulators of taar; preparation procedure; pharmaceutical composition; and its use in the treatment of depression, anxiety disorders, bipolar disorder, schizophrenia, epilepsy, migraine, Alzheimer's disease, metabolic disorders, among others. | |
CL2008000434A1 (en) | COMPOUNDS DERIVED FROM 2-AMINO-OXAZOLINAS; OBTAINING PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DEPRESSION, ANXIETY, STRESS, BIPOLAR DISORDER, AMONG OTHERS. | |
ECSP067021A (en) | COMPOUNDS AND COMPOSITIONS AS RECEPTOR MODULATORS ACTIVATED BY PEROXISOM PROLIFERATOR (PPAR) | |
CL2011000144A1 (en) | Compounds derived from benzo (1,4) dioxin-2-ylmethyl-sulfamide; pharmaceutical compositions containing them; process to prepare them and use in the treatment of anxiety, epilepsy, pain, substance abuse, related disorders, among others. | |
CL2007002970A1 (en) | COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS. | |
HN2008001720A (en) | ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS | |
BR122019021238B8 (en) | use of an interleukin-6 (il-6) receptor inhibitor in the treatment of graft versus host disease (gvhd) | |
CL2008002162A1 (en) | Compounds derived from 3-benzoisoxazole-piperidine; pharmaceutical composition comprising said compounds; and its use for the treatment and / or prevention of cognitive disorders, drug addiction, depression, anxiety, among others. | |
CL2008001114A1 (en) | Compounds derived from benzimidazole; pharmaceutical composition; and use in the treatment of diseases such as overactive bladder, pain, obesity, seizures, among others. | |
CL2007003832A1 (en) | COMPOUNDS DERIVED FROM AZAESPIRO; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE TO PREVENT AND TREAT ANXIETY, DEPRESSIVE DISORDERS, AMONG OTHER DISEASES. | |
UY28876A1 (en) | SUBSTITUTED MORPHOLINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | |
SV2010003662A (en) | DERIVATIVES OF AZETIDINE AND CYCLLOBUTANE AS JAK INHIBITORS REF. X-19081 | |
CL2007002635A1 (en) | Quinazolinone and isoquinolinone derived compounds, modulators of hpa axis activity; pharmaceutical composition comprising them; and its use in the treatment and / or prevention related to stress or depression. | |
CR11849A (en) | MIXED AGONISTS, BASED ON GIP FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY | |
EA201001329A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
UY32926A (en) | COMPOUNDS AS ANTAGONISTS OF LISOPHOSPHATIDIC ACID RECEPTORS | |
EA201001332A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
CL2008001465A1 (en) | Compounds derived from [2,1,3] benzoxadiazole-5-carboxamides, modulators of ampa receptors; pharmaceutical compositions; and its use in the treatment of hypoglutamatergic conditions, cognitive disorders, parkinson's disease, adhd, rett syndrome, respiratory depression, fragile x syndrome, and Alzheimer's disease. | |
UY32937A (en) | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | |
ECSP099061A (en) | BENZOFUR- AND BENZOTIENOPIRIMIDINE MODULATORS | |
CL2008002247A1 (en) | Compounds derived from phenyl amide; Preparation process; pharmaceutical composition containing them; and its use in the preparation of drugs for the treatment of sleep disorders, narcolepsy and psychiatric disorders, among others. | |
EA201001330A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
CL2011002160A1 (en) | Compounds derived from substituted 3-amino-2-mercaptoquinolines; pharmaceutical composition containing said compounds; and its use to treat pain, epilepsy, urinary incontinence, manias, migraine, bipolar disorders, cognitive diseases, dyskinesia associated with dystonia and / or urinary incontinence. |